Stem cell therapy: a potential cure for hearing loss?

The dawn of the 21st century witnessed the success of the Human Genome Project, the quiver of the Braille glove and the ease of obtaining both an ancestry profile and a diagnosis for genetic disorders from a do-it-yourself at-home DNA test kit. Advancements in healthcare since then have been aplenty with various new therapies revolutionizing oncological studies; a promising one being regenerative cell therapy. Although cell therapy was first performed in 1958 when French oncologist Georges Mathe transplanted bone marrow stem cells after six nuclear researchers were accidentally exposed to radiation, research picked up pace in the 2000s with the development of induced pluripotent stem (iPS) cells by Japanese researcher Shinya Yamanaka in 2006. These cells, which mimic transient embryonic stem cells, are derived from skin and blood cells that are reprogrammed into a pluripotent state, enabling them to be differentiated into any cell in the human body

Read more
Stem Cell Research Article, Embryonic Cells Information, Cell Therapy …

In the beginning, one cell becomes two, and two become four. Being fruitful, they multiply into a ball of many cells, a shimmering sphere of human potential. Scientists have long dreamed of plucking those naive cells from a young human embryo and coaxing them to perform, in sterile isolation, the everyday miracle they perform in wombs: transforming into all the 200 or so kinds of cells that constitute a human body. Liver cells. Brain cells

Read more
QBRI concludes stem cells symposium – Gulf Times

The Qatar Biomedical Research Institute (QBRI) at Hamad Bin Khalifa University has concluded the Translational Advances in Stem Cells for Diabetes Symposium, organised by the Steering Committee of Qatar Biomedical Research Institute (QBRI)-Harvard Stem Cell Institute (HSCI) Agreement.The two-day event at Minaretein on the HBKU campus in Education City, Doha, aimed to promote research interaction and collaboration at the intersection of diabetes and stem cell biology, a statement said.The symposium featured a panel discussion during the conference, titled Stem cell therapy for diabetes: from basic science to clinical translation. The discussion was moderated by Dr Essam Abdelalim, scientist at QBRI and chair of the Steering Committee of the QBRI-HSCI Agreement, and featured esteemed experts.They included Prof Camillo Ricordi, director of the Diabetes Research Institute and the Cell Transplant Center, University of Miami; Prof Kenji Osafune, head, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University; Dr Adrian Teo, principal investigator, Institute of Molecular and Cell Biology, Singapores Agency for Science, Technology, and Research; Prof Dr Matthias Hebrok, director, Center for Organoid Systems and Tissue Engineering, Technical University Munich.The keynote speeches were from renowned scientists in the fields of diabetes and stem cells, including Dr Ramona Pop, interim research director, Melton Lab, Harvard Stem Cell Institute; and Prof Miriam Cnop, director, Center for Diabetes Research, Universit Libre de Bruxelles as well as multiple local speakers.Participants presented cutting-edge research in this field, including stem cell-derived pancreatic islets for cell therapy, the understanding of diabetes pathogenesis using stem cells, the establishment of clinically relevant iPSCs, and precision medicine in diabetes.Dr Omar Albagha, acting executive director of QBRI, said "the discussions and presentations were insightful and inspiring, and we hope they will lead to further advancements in stem cell therapy for diabetes. This event also highlights QBRI's dedication to supporting cutting-edge research that has the potential to positively impact the lives of people with diabetes."Dr Abdelalim said: "By fostering collaboration and knowledge-sharing, we can accelerate the pace of scientific discovery and ultimately improve patient outcomes."The successful conclusion of the symposium is a testament to QBRI's commitment to promoting research collaboration and advancing knowledge in the field of stem cell therapy for diabetes. QBRI looks forward to hosting more events that will facilitate the exchange of ideas and help accelerate progress in diabetes research, the statement added.

Read more
2020 California Proposition 14 – Wikipedia

From Wikipedia, the free encyclopedia Citizen-initiated ballot measure For 60%70% 50%60% Against 70%80% 60%70% 50%60% California Proposition 14 is a citizen-initiated ballot measure that appeared on the ballot in the 2020 California elections, for November 3, 2020. It authorizes state bonds to be issued worth $5.5 billion, which will fund the California Institute for Regenerative Medicine (CIRM), which serves as the state's center for stem cell research, and enable it to continue its operations.[1][2][3] This measure passed with 51% of the vote.[2] Robert N. Klein II, motivated by the suffering of family members from autoimmune diseases, launched a citizen initiative known as Proposition 71 in 2004, which created a state-funded center for stem cell research - the California Institute for Regenerative Medicine (CIRM).[4] Based in San Francisco, the CIRM is responsible for with making grants and loans to stem cell research initiatives focused on developing treatment methods and completing research for clinical trials.[5] Proposition 71 was approved by 59% of California voters and authorized $3 billion in bonds to fund the CIRM in addition to creating a Governing Board of 29 members as an Independent Citizens' Oversight Committee (ICOC).[6] By 2020, $2.75 billion of the original $3 billion has been used or earmarked for funding of basic research, infrastructure, education, and clinical translational studies.[7] For this reason, Klein spearheaded this initiative to authorize an additional $5.5 billion in bonds for the CIRM to support additional grants and operations under Proposition 14.[8] Research areas of focus at CIRM include stem cell based research to mitigate or cure serious illness and chronic diseases such as cancer, heart disease, kidney disease, respiratory illnesses including COVID-19, diabetes, cancer, HIV/AIDs, paralysis, blindness, and more. A dedicated $1.5 billion under funding from Proposition 14 will be dedicated to research of diseases specific to the central nervous system and brain, including cancer, autism, dementia, Parkinson's and Alzheimers' disease.[9] Changes to the CIRM program and governance proposed in Proposition 14 include increased focus in improving patient access to stem cell treatments by expanding sites and facilities for human trials, the requirement for income earned from CIRM agreements to reduce the cost of stem cell treatments for patients, increase the ICOC from 29 members to 35 members, and to hire 15 full-time employees whose roles are dedicated to improving patient access to stem cell-derived therapeutics and treatments.[10] Further, proposition 14 stipulates $1.5 billion to be spent researching brain and nervous system diseases, including dementia and Parkinson's disease.[11] Estimated fiscal impact of Proposition 14 would include the initial $5.5 billion in bonds and $2.5 billion in interest, for an overall annual debt payment of $310 million over 25 years.[10] Proposition 14 appropriates money from the general fund in order to fully pay the bond debt service.[11] In addition to Klein, this measure is supported by the Regents of the University of California.[2] It was also endorsed by governor Gavin Newsom and The Modesto Bee.[12] Proponents argue that biomedical research is crucial, particularly in light of the COVID-19 pandemic.[13] Proponents of Proposition 14 have raised more than $13.4 million in campaign funds.[14] As with Proposition 71, opposition to Proposition 14[15] includes many across the political spectrum including the Bakersfield Californian, California Nurses Association, California Catholic Conference,[16] California Republican Party, Center for Genetics and Society,[8] Friends Committee on Legislation of California, Green Party of California, Howard Jarvis Taxpayers Association, Libertarian Party of California, Los Angeles Times, Orange County Register, Peace and Freedom Party, Right to Life of Central California,[17] San Bernardino Sun, San Francisco Chronicle, San Jose Mercury News, Scholl Institute of Bioethics, and CIRM board member Jeff Sheehy

Read more
Stem Cell Reports | Journal | ScienceDirect.com by Elsevier

Stem Cell Reports is an open access forum communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on shorter, single-point manuscripts that report original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians. Given the rapidly increasing impact of stem cell research to regenerative medicine and tissue engineering, Stem Cell Reports encourages the submission of manuscripts whose scope bridges these fields of research.

Read more
Stem cell therapy MSC-NP found to ease inflammatory activity of brain …

MSC-NP, a form of stem cell therapy thats currently in early clinical trials for multiple sclerosis (MS), can reduce the inflammatory activity of brain immune cells called microglia, according to a new study. The therapy is known to reduce disease severity and improve myelin regeneration in animal models of MS, and the findings suggest it may be doing so at least in part by modulating the activity of microglia

Read more
Stem Cell Research | Office of Research Compliance | SIU

Human stem cell research at SIUC, regardless of funding source, must be approved by the Stem Cell Research Oversight (SCRO) Committee before the research can begin. Review by the SCRO Committee does not supplant review by other relevant review committees; see the policy and procedures linked below. The committee has final approval over stem cell projects.

Read more
Heart disease study shows hope for stem cell treatment

Researchers have tried for decades to use stem cells to restore a damaged heart. A new study shows they still haven't succeeded, but it offers the first glimmers of hope for heartdisease, whichis blamed for about 1 in 5 deaths in the United States, killingnearly 700,000 people a year. The trial, by the Texas Heart Institute, showed that a one-time treatment of cells didn't keep heart failurepatients out of the hospital.

Read more